Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 3Active not recruiting 3Terminated 2Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Recurrence 1Gastro-enteropancreatic neuroendocrine tumor 1Acromegaly 1

Interventions

pembrolizumab 111Carboplatin 45Nivolumab 41Paclitaxel 34Cyclophosphamide 32Cisplatin 32Gemcitabine 30atezolizumab 27Specimen Handling 25venetoclax 24Magnetic Resonance Spectroscopy 24Pemetrexed 23fludarabine 22Biopsy 22Radiotherapy 21Ipilimumab 21Docetaxel 21Bevacizumab 21Azacitidine 21Radiosurgery 18durvalumab 17Fluorouracil 17Dexamethasone 17Cetuximab 16fludarabine phosphate 14Trastuzumab 14Leucovorin 13Cytarabine 13tislelizumab 12olaparib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Octreotide × 1 year × Clear all
NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

NCT05364944 2025-11-17

OXTEND-01

Debiopharm International SA

Phase 1 Terminated
19 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

Data powered by HemOnc (CC BY 4.0) Colophon âš¡